Recipharm, LIDDS establish industrial manufacturing capabilities for prostate cancer drug

The manufacturing line is dedicated to the first product based on LIDDS’ innovative NanoZolid technology

Recipharm, the contract development and manufacturing organisation (CDMO), and LIDDS have together set up a manufacturing line for LIDDS’ novel prostate cancer drug, LiprocaDepot, at Recipharm in Solna, Sweden.

The manufacturing line is dedicated to the first product based on LIDDS’ innovative NanoZolid technology. Clinical trial material has already been produced and the facility is ready for future commercial manufacturing of Liproca Depot or other pharmaceutical formulations based on the NanoZolid technology. The manufacturing line has been adapted for GMP production and is industrialised according to a unique process invented by LIDDS, involving the installation of novel equipment that is new to the pharmaceutical industry.